Camrelizumab Plus Apatinib Combined with POF in Patients with Untreated Advanced Gastric Cancer (UAGC): A Single-center, Open-Label, Single-Arm, Phase II Trial (SYLT-017).
Apatinib;Camrelizumab;POF
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Camrelizumab Plus Apatinib Combined with POF in Patients with Untreated Advanced Gastric Cancer (UAGC): A Single-center, Open-Label, Single-Arm, Phase II Trial (SYLT-017). ### Output: Apatinib;Camrelizumab;POF